Darolutamide improves overall survival in mHSPC
Adding darolutamide to docetaxel and androgen deprivation therapy significantly improved overall survival in men with metastatic hormone-sensitive prostate cancer.
Related Articles
Published OASIS trial data show safety, efficacy of Revi system for OAB
Findings from the study showed a clinical response rate of 76.4% and 78.4% at 6- and 12-months following activation of the device among patients in…
How to bill for performing complex urodynamics
“To answer this question, one must know what is and is not included in the global payment for the UDS, and the definition and instructions…
FDA approves NMIBC treatment nogapendekin alfa-inbakicept/BCG
The median duration of CR in those who experienced a response to treatment was 26.6 months (95% CI, 9.9-not reached [NR]).
Experts develop guide on online tools to reduce costs of urologic drugs
“At a time when patients are increasingly concerned about prescription drugs, this information will provide a useful starting point for making essential medications as affordable…
Dr. Haile discusses medical management of BPH
“Alpha-blockers are often, for patients, the first line of treatment because they help quickly relax the smooth muscles in the bladder and the prostate,” says…
Dr. Wolf on the CVAC System for steerable ureteroscopic renal evacuation
“I cannot overstate the impact of this device on my management of kidney stone patients,” says J. Stuart Wolf, Jr., MD, FACS.
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
“This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who…
Urologist encourages consideration of early apical release HoLEP technique
“For those who do enucleations, I think I would encourage people to highly consider adopting an apical release technique if they haven’t,” says Daniel J.…
Dr. Pienta on the evolving paradigm of PSMA-PET imaging
“The advance of PSMA imaging has put an emphasis on multidisciplinary care,” says Kenneth J. Pienta, MD.
212Pb SPECT/CT imaging shows initial benefit, feasibility in mCRPC
“In the future, this imaging technique can help to streamline the drug development process, driving conviction in the agents we bring to larger scale trials,”…